Literature DB >> 17116003

Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.

T Lundåsen1, C Gälman, B Angelin, M Rudling.   

Abstract

Bile acids (BAs) traversing the enterohepatic circulation exert several important metabolic effects. Their hepatic synthesis, controlled by the enzyme cholesterol 7alpha-hydroxylase (CYP7A1), has a unique diurnal variation in man. Here we provide evidence that the transintestinal flux of BAs regulates serum levels of intestinal fibroblast growth factor 19 (FGF19) that in turn modulate BA production in human liver. Basal FGF19 levels varied by 10-fold in normal subjects, and were reduced following treatment with a BA-binding resin and increased upon feeding the BA chenodeoxycholic acid. Serum FGF19 levels exhibited a pronounced diurnal rhythm with peaks occurring 90-120 min after the postprandial rise in serum BAs. The FGF19 peaks in turn preceded the declining phase of BA synthesis. The diurnal rhythm of serum FGF19 was abolished upon fasting. We conclude that, in humans, circulating FGF19 has a diurnal rhythm controlled by the transintestinal BA flux, and that FGF19 modulates hepatic BA synthesis. Through its systemic effects, circulating FGF19 may also mediate other known BA-dependent effects on lipid and carbohydrate metabolism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116003     DOI: 10.1111/j.1365-2796.2006.01731.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  160 in total

1.  Upregulation of hepatic bile acid synthesis via fibroblast growth factor 19 is defective in gallstone disease but functional in overweight individuals.

Authors:  Olga Renner; Simone Harsch; Silke Matysik; Dieter Lütjohann; Gerd Schmitz; Eduard F Stange
Journal:  United European Gastroenterol J       Date:  2014-06       Impact factor: 4.623

Review 2.  Getting the mOST from OST: Role of organic solute transporter, OSTalpha-OSTbeta, in bile acid and steroid metabolism.

Authors:  Paul A Dawson; Melissa L Hubbert; Anuradha Rao
Journal:  Biochim Biophys Acta       Date:  2010-06-09

3.  Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice.

Authors:  Johanna H M Stroeve; Gemma Brufau; Frans Stellaard; Frank J Gonzalez; Bart Staels; Folkert Kuipers
Journal:  Lab Invest       Date:  2010-06-07       Impact factor: 5.662

4.  Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity.

Authors:  Tiangang Li; Jessica M Francl; Shannon Boehme; Adrian Ochoa; Youcai Zhang; Curtis D Klaassen; Sandra K Erickson; John Y L Chiang
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

Review 5.  Endocrine fibroblast growth factors 15/19 and 21: from feast to famine.

Authors:  Matthew J Potthoff; Steven A Kliewer; David J Mangelsdorf
Journal:  Genes Dev       Date:  2012-02-02       Impact factor: 11.361

6.  Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition.

Authors:  Benjamin Schmidt; Lan Wei; Danielle K DePeralta; Yujin Hoshida; Poh Seng Tan; Xiaochen Sun; Janelle P Sventek; Michael Lanuti; Kenneth K Tanabe; Bryan C Fuchs
Journal:  Int J Cancer       Date:  2015-11-09       Impact factor: 7.396

Review 7.  Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.

Authors:  Chiara Degirolamo; Carlo Sabbà; Antonio Moschetta
Journal:  Nat Rev Drug Discov       Date:  2015-11-16       Impact factor: 84.694

8.  Managing bile acid diarrhoea.

Authors:  Julian R F Walters; Sanjeev S Pattni
Journal:  Therap Adv Gastroenterol       Date:  2010-11       Impact factor: 4.409

9.  FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action.

Authors:  Dong-Ju Shin; Timothy F Osborne
Journal:  J Biol Chem       Date:  2009-02-23       Impact factor: 5.157

Review 10.  Bile acids: chemistry, physiology, and pathophysiology.

Authors:  Maria J Monte; Jose J G Marin; Alvaro Antelo; Jose Vazquez-Tato
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.